This case presents a professional ethics and public safety dilemma — a superior is instructing an engineer to certify work that poses known safety risks to the public. The Chief Engineer's verbal advice to ignore the deviations has no legal standing and cannot transfer the signing officer's personal accountability.

Ethical anchor: Article 21's right to life is at stake — a structurally deficient flyover used by thousands daily is a latent rights violation waiting to materialise. The Institution of Engineers India's Code of Ethics places public safety above client and employer interest. Kantian ethics: if every executive engineer ignored structural deviations under superior pressure, no public infrastructure would be safe — the universalisability test fails.

Option evaluation: Following the verbal advice means accepting personal criminal liability for future structural failure — this cannot be done. Seeking transfer abandons the problem without resolving it and allows the unsafe structure to be certified by the next engineer. The correct sequence is: first, request the CE's instruction in writing — he will almost certainly refuse to document improper advice, which neutralises the pressure. Simultaneously issue formal correction notices to the contractor — this creates an official record regardless of the CE's position. If the CE persists, escalate to the Superintending Engineer and Chief Secretary with full documentation. The false certifications by junior engineers must also be separately reported through the vigilance channel.

My decision: I would not ignore the deviations. I would request the written order, issue correction notices, and escalate if necessary. I will not sign any completion certificate for work that fails structural safety standards.

Reform: All major public infrastructure projects should have a mandatory independent third-party structural safety audit before commissioning — entirely separate from the project's own engineering hierarchy — removing the conflict of interest inherent in self-certification.

Why this keeps happening nationally — root causes:

Regulatory failure: Municipal building approval processes in India are opaque, slow, and corruption-prone. Illegal extensions happen with the tacit knowledge of building inspectors who are either complicit (bribed to look away) or absent (insufficient inspection capacity). A building extended from 3 to 6 floors does not happen overnight — it happened over months or years with no effective enforcement response.

Demand-supply mismatch: In fast-growing cities, the demand for construction far exceeds the formal housing stock. Builders respond to this demand by adding floors illegally because the penalty risk is low and the financial return is high. Until the penalty structure makes non-compliance economically irrational, the incentive pattern does not change.

Migrant labour vulnerability: Construction workers — particularly migrant workers — are among the most systematically unprotected workers in India. The Building and Other Construction Workers Act, 1996 mandates registration, safety equipment, and welfare contributions — implementation is weak. Workers have no leverage to refuse unsafe worksites because their informal employment status means refusal equals job loss with no social protection.

Preventive measures:

1. Mandatory third-party structural audits for all buildings above G+2, conducted by BIS-accredited independent engineers before each floor addition is permitted — removing the corrupt inspector as the sole safety gate.

2. Real-time building monitoring technology: Satellite-based or drone-enabled monitoring of construction sites against approved plans — many states have piloted this; it needs scaling to urban local bodies nationally.

3. BOCW Act enforcement: All construction workers must be registered under the Building and Other Construction Workers Act, 1996 before site work begins — making worker welfare fund contributions and safety equipment mandatory as a site licensing condition.

4. Developer liability reform: Stricter personal liability for builders, engineers who certified the plans, and inspectors who cleared the site — the current penalty structure does not create genuine deterrence. Criminal liability for manslaughter under BNS 2023 must be systematically pursued, not just arrested-and-bailed.

5. Migrant worker rights: Portable registration under BOCW linked to Aadhaar — so workers who move between sites retain their benefits and can report safety violations without losing employment protection.

Reform anchor: Urban local bodies must be empowered with adequate inspection staff and digital monitoring tools — not one inspector per hundred construction sites, which is the current reality in most tier-2 cities.

This case presents three simultaneous pressures designed to test whether any combination of institutional, political, and personal incentives can override a documented safety obligation. The answer is no — and the response must address each pressure individually.

Ethical issues: A structural crack in an elevated corridor pier is not a cosmetic defect — it signals potential compromise of load-bearing capacity. An elevated corridor that collapses during public use will kill people. The project manager's professional duty — grounded in Art. 21, the National Building Code, and the IEI Code of Ethics — is unambiguous: document the defect, recommend rectification, and refuse to certify safe completion of a structure that is not safe.

On the three pressures: The electoral deadline is irrelevant — no political calendar determines structural engineering safety standards. If the Minister wants an inauguration before elections, he can inaugurate a section that is genuinely complete. The contractor's relationship with the Minister creates a conflict of interest that strengthens, not weakens, the case for independent safety assessment — it is precisely when the oversight authority has a personal connection to the contractor that independent professional assessment becomes most important. The promotion hint is the most insidious pressure because it is personal. But accepting a promotion as compensation for falsely certifying an unsafe structure is bribery in the form of career advancement — it converts the project manager from a safety officer into a complicit party in potential manslaughter.

Options and my decision: First, issue a formal written technical report documenting the crack, the structural assessment, and the required rectification — this creates an official record that cannot be suppressed verbally. Second, request the Chief Engineer to put his overruling instruction in writing with his technical justification — he will not do this. Third, if the CE persists orally, escalate in writing to the Chief Secretary and state government with the full technical documentation. Fourth, refuse to sign the completion certificate for the defective section under any circumstance.

Reform: A mandatory independent structural safety certification for all elevated infrastructure — separate from the project's engineering hierarchy — by a third-party BIS-accredited firm before commissioning would remove the project manager from this impossible position entirely by making independent safety certification a legal prerequisite for inauguration.

This case tests integrity under the most personal form of pressure — existential career threat with family dependents. The examiner expects you to acknowledge the genuine personal cost while explaining clearly why the professional obligation cannot be waived.

Ethical issues: Three issues are present. A quality certification is a public representation — when a quality inspector signs a clearance, they are representing to every consumer who buys that product that it meets declared standards. Signing the clearance for a product the inspector has documented as defective is a false representation — regardless of how it was obtained. The domestic consumer has the same right to safe, quality products as the export customer. Selling rejected export products in the domestic market because Indian consumers have "less recourse" than foreign buyers is a form of discrimination that violates the Consumer Protection Act, 2019 and Art. 21. The termination threat, however real, does not create permission to issue a false quality certification — the signature is still false regardless of the circumstances under which it was obtained.

Options: First, refuse to sign the clearance. This is the non-negotiable baseline. Second, document the management's pressure — the overruling instruction and the termination threat — in writing (email, formal note to file). This creates a record of coercion that protects the inspector if legal proceedings follow. Third, file a complaint with the Consumer Affairs Ministry and the BIS (Bureau of Indian Standards) regarding the company's practice of clearing rejected export consignments for domestic sale — this is reportable independent of the employment decision. Fourth, consult a labour lawyer regarding the termination threat — wrongful termination for refusing to sign a false quality certification may itself be actionable.

On the personal vulnerability: The family situation creates a genuine and painful cost. But signing a false certification does not actually secure the job long-term — it makes the inspector complicit in a practice that will eventually be discovered, producing worse consequences. And practically: an experienced quality inspector is more employable than a blacklisted one with a fraud on their record.

Reform: Quality inspectors should have legal whistleblower protection — equivalent to the WPA 2014 for government employees — when they refuse to sign false certifications. Currently, private sector quality professionals have no formal protection mechanism for such refusals.

My position as Dr. Srinivasan: I would refuse all three shortcuts. Not because they are collectively impermissible, but because each one independently crosses a line that medical ethics cannot accept.

Shortcut 1 — Manipulating data: Data manipulation in drug trials is not "cutting corners" — it is the systematic creation of false evidence about drug safety and efficacy. When a drug based on manipulated trial data reaches patients, those patients are being treated on the basis of a lie. If the drug has undisclosed adverse effects that the manipulation concealed, patients will be harmed at scale. The Drugs and Cosmetics Act, the ICMR Ethical Guidelines, and every international research ethics framework treat data manipulation as a fundamental violation — it is not merely unethical, it is criminal under the D&C Act. Historical context: the thalidomide tragedy — where manipulated or incomplete data led to severe fetal deformities — remains the defining case for why drug trial integrity is non-negotiable.

Shortcut 2 — Skipping informed consent: Informed consent is not a procedural formality — it is the patient's right to decide what happens to their own body. The ICMR Guidelines 2017 and the Helsinki Declaration make informed consent an absolute requirement. Skipping it treats trial participants as means to a commercial end rather than as autonomous persons with rights. This is a Kantian violation of the most fundamental kind: using human bodies as instruments for first-mover commercial advantage. The Nuremberg Code — established after Nazi medical experiments — created the absolute requirement for informed consent precisely to prevent this logic from being accepted.

Shortcut 3 — Using a rival's patented compound without authorisation: This is intellectual property theft — industrial espionage with a medical dimension. Beyond the legal consequences (patent infringement, potential criminal liability), it creates a situation where the drug's active compound cannot be publicly disclosed, preventing other researchers from independently verifying the trial results. The scientific integrity of the entire trial is compromised.

What I would do: Refuse all three. Document the pressure from senior members in writing — this protects me and creates an institutional record. Report the suggestions to the institutional ethics committee and, if necessary, to the ICMR and CDSCO. Simultaneously, present alternative legitimate pathways for accelerating the timeline: adaptive trial design (already approved by regulators), emergency use authorisation process, compassionate use protocol for the most severe cases. These are the legitimate mechanisms for emergency drug development — they exist precisely for situations like this.

How data ethics and drug ethics save humanity: Trust in medical research is itself a global public good. When trials are manipulated, patients and healthcare systems lose confidence in all research — reducing vaccine uptake, creating barriers to legitimate treatments, and costing more lives than any first-mover advantage could save. The COVID-19 vaccine rollout demonstrated both dimensions: the extraordinary speed of legitimate accelerated trials (Operation Warp Speed, Covishield) and the harm caused by misinformation about compromised trials. Data integrity is what makes the entire ecosystem of medical progress possible.

Reform: An independent trial data depository — where raw trial data is uploaded in real time to a regulatory authority-monitored system — would make data manipulation structurally difficult rather than merely ethically prohibited. This is the model used in some EU jurisdictions and must be adopted for all human trials in India.

This case tests whether a CEO understands that "no commercial return" does not end the analysis — it begins it. Multiple legal, institutional, and ethical mechanisms exist for exactly this situation, and a CEO who is genuinely committed to both their business and their responsibilities as a corporate citizen will know them.

Ethical framing: The tribal population with an incurable liver disease holds an Art. 21 right to life that is being structurally denied by the inaccessibility of a potential cure. The company that possesses the scientific knowledge to develop this cure has an ethical obligation — and potentially a legal one under CSR provisions of the Companies Act, 2013 — to engage with this situation rather than simply decline on commercial grounds.

Options available and their analysis:

1. Decline R&D — no commercial return. Legally permissible. Ethically weak. Ignores the CSR obligation under Companies Act s.135 (2% of net profit for qualifying companies) and the reputational and commercial value of being associated with a life-saving discovery. Option: the worst one.

2. Pursue R&D fully funded by the company. The most ethically complete option. CSR funding can legitimately be applied to tribal health outcomes. The reputational value of developing a cure for an incurable tribal disease may produce commercial return through goodwill, government partnerships, and brand value that the narrow financial calculation misses. Pros: fulfils ethical and CSR obligations, positions the company as a responsible innovator. Cons: ₹50 crore investment with uncertain direct return.

3. Public-Private Partnership with government / ICMR. The most practically sustainable path: the company provides the compound and scientific expertise; the government and ICMR provide co-funding for the trial and regulatory pathway; the government purchases the eventual drug at a negotiated price for public health distribution. This converts a losing commercial proposition into a shared public health investment. Many breakthrough drugs have been developed through this model.

4. Compulsory licensing application by government. If the company declines R&D, the government can apply for a compulsory licence under Patents Act s.84 (insufficient working of patent to the reasonable requirements of the public) — the Doha Declaration on TRIPS and Public Health explicitly recognises public health emergencies as grounds for compulsory licensing. The company's best response is to engage with option 2 or 3 before the government exercises this option.

My recommendation as CEO: Pursue option 3 — a PPP structure. Engage ICMR and the Ministry of Health, propose a co-funded development pathway, with government purchase commitment for distribution in tribal areas. The ₹50 crore cost is shared; the reputational and relationship capital gained is significant; and the Art. 21 obligation is honoured.

Reform: India's CSR framework should explicitly include rare and neglected tropical diseases affecting tribal populations as priority CSR areas — creating tax incentives for pharmaceutical companies to invest in low-return high-impact research that the market alone will not fund.